How pharma could benefit from one of Congress’ signature drug pricing ideas

If you asked me in January whether Congress would stick it to pharma this Congress, I’d say the odds were pretty darn good. Now I’m not only doubting Congress will inflict any pain on the industry, I’m starting to think the so-called reforms both Republicans and Democrats are pushing may leave the industry better off than when Congress gaveled in this January.